GRT Capital Partners L.L.C. continued to hold its position in Stryker Corporation (NYSE:SYK) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 4,389 shares of the medical technology company’s stock at the close of the second quarter. GRT Capital Partners L.L.C.’s holdings in Stryker Corporation were worth $609,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of SYK. Bollard Group LLC grew its holdings in shares of Stryker Corporation by 0.4% during the second quarter. Bollard Group LLC now owns 832 shares of the medical technology company’s stock worth $115,000 after buying an additional 3 shares in the last quarter. Motco grew its holdings in shares of Stryker Corporation by 50.7% during the second quarter. Motco now owns 826 shares of the medical technology company’s stock worth $115,000 after buying an additional 278 shares in the last quarter. James Investment Research Inc. bought a new position in shares of Stryker Corporation during the second quarter worth about $155,000. Guardian Life Insurance Co. of America grew its holdings in shares of Stryker Corporation by 0.8% during the first quarter. Guardian Life Insurance Co. of America now owns 1,199 shares of the medical technology company’s stock worth $158,000 after buying an additional 9 shares in the last quarter. Finally, Assetmark Inc. grew its holdings in shares of Stryker Corporation by 0.3% during the first quarter. Assetmark Inc. now owns 1,274 shares of the medical technology company’s stock worth $168,000 after buying an additional 4 shares in the last quarter. Institutional investors and hedge funds own 74.13% of the company’s stock.

Shares of Stryker Corporation (NYSE SYK) opened at 148.31 on Friday. The firm has a market capitalization of $55.48 billion, a PE ratio of 33.10 and a beta of 0.80. The stock has a 50 day moving average price of $142.34 and a 200-day moving average price of $139.87. Stryker Corporation has a 52-week low of $106.48 and a 52-week high of $148.84.

Stryker Corporation (NYSE:SYK) last released its earnings results on Thursday, July 27th. The medical technology company reported $1.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.51 by $0.02. The company had revenue of $3.01 billion during the quarter, compared to analyst estimates of $2.98 billion. Stryker Corporation had a return on equity of 24.26% and a net margin of 14.22%. Stryker Corporation’s quarterly revenue was up 6.1% on a year-over-year basis. During the same period in the prior year, the company posted $1.39 earnings per share. Equities analysts forecast that Stryker Corporation will post $6.46 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, October 31st. Stockholders of record on Friday, September 29th will be issued a $0.425 dividend. This represents a $1.70 annualized dividend and a dividend yield of 1.15%. The ex-dividend date of this dividend is Thursday, September 28th. Stryker Corporation’s dividend payout ratio is presently 37.95%.

A number of research analysts recently issued reports on the company. Royal Bank Of Canada reiterated a “buy” rating and set a $155.00 price objective on shares of Stryker Corporation in a report on Monday. SunTrust Banks, Inc. reiterated a “buy” rating and set a $161.00 price objective on shares of Stryker Corporation in a report on Monday. BidaskClub upgraded Stryker Corporation from a “hold” rating to a “buy” rating in a report on Thursday, August 17th. Cowen and Company reiterated a “buy” rating and set a $160.00 price objective (up from $150.00) on shares of Stryker Corporation in a report on Sunday, July 30th. Finally, Zacks Investment Research downgraded Stryker Corporation from a “buy” rating to a “hold” rating in a report on Wednesday, August 23rd. Two analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $146.78.

TRADEMARK VIOLATION WARNING: This story was posted by Watch List News and is owned by of Watch List News. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international copyright legislation. The legal version of this story can be read at https://www.watchlistnews.com/stryker-corporation-syk-stake-maintained-by-grt-capital-partners-l-l-c/1611895.html.

In other news, insider David Floyd sold 19,305 shares of the company’s stock in a transaction that occurred on Wednesday, July 12th. The stock was sold at an average price of $144.56, for a total value of $2,790,730.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Lonny J. Carpenter sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, August 4th. The shares were sold at an average price of $146.36, for a total value of $731,800.00. Following the completion of the transaction, the insider now directly owns 88,207 shares of the company’s stock, valued at $12,909,976.52. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 25,429 shares of company stock valued at $3,686,927. 7.40% of the stock is currently owned by corporate insiders.

About Stryker Corporation

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Institutional Ownership by Quarter for Stryker Corporation (NYSE:SYK)

Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.